132 related articles for article (PubMed ID: 20947152)
1. CA 125 normalization with chemotherapy is independently predictive of survival in advanced endometrial cancer.
Hoskins PJ; Le N; Correa R
Gynecol Oncol; 2011 Jan; 120(1):52-5. PubMed ID: 20947152
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for prolonged survival in recurrent endometrial carcinoma: Implications for follow-up protocol.
Otsuka I; Uno M; Wakabayashi A; Kameda S; Udagawa H; Kubota T
Gynecol Oncol; 2010 Dec; 119(3):506-10. PubMed ID: 20837356
[TBL] [Abstract][Full Text] [Related]
3. Measurement of the minimum apparent diffusion coefficient (ADCmin) of the primary tumor and CA125 are predictive of disease recurrence for patients with endometrial cancer.
Nakamura K; Imafuku N; Nishida T; Niwa I; Joja I; Hongo A; Kodama J; Hiramatsu Y
Gynecol Oncol; 2012 Feb; 124(2):335-9. PubMed ID: 22008707
[TBL] [Abstract][Full Text] [Related]
4. Comparison of the efficacy between paclitaxel/carboplatin and doxorubicin/cisplatin for concurrent chemoradiation in intermediate- or high-risk endometrioid endometrial cancer: a single institution experience.
Kim HS; Kim JW; Wu HG; Chung HH; Park NH; Song YS; Kang SB; Lee HP
J Obstet Gynaecol Res; 2010 Jun; 36(3):598-604. PubMed ID: 20598043
[TBL] [Abstract][Full Text] [Related]
5. The predictive and prognostic value of serum CA 125 half-life during paclitaxel/platinum-based chemotherapy in patients with advanced ovarian carcinoma.
Gadducci A; Cosio S; Fanucchi A; Negri S; Cristofani R; Genazzani AR
Gynecol Oncol; 2004 Apr; 93(1):131-6. PubMed ID: 15047226
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of serum CA-125 levels for preoperative counseling in endometrioid endometrial cancer: a multi-center study.
Kim HS; Park CY; Lee JM; Lee JK; Cho CH; Kim SM; Kim JW
Gynecol Oncol; 2010 Sep; 118(3):283-8. PubMed ID: 20541245
[TBL] [Abstract][Full Text] [Related]
7. Use of preoperative serum CA-125 levels for prediction of lymph node metastasis and prognosis in endometrial cancer.
Chung HH; Kim JW; Park NH; Song YS; Kang SB; Lee HP
Acta Obstet Gynecol Scand; 2006; 85(12):1501-5. PubMed ID: 17260229
[TBL] [Abstract][Full Text] [Related]
8. Serum CA-125 level after 6 cycles of primary adjuvant chemotherapy is a useful prognostic factor for complete responders' survival in patients with advanced epithelial ovarian cancer.
Kim HS; Park NH; Chung HH; Kim JW; Song YS; Kang SB
Onkologie; 2008 Jun; 31(6):315-20. PubMed ID: 18547972
[TBL] [Abstract][Full Text] [Related]
9. Adjuvant carboplatin and paclitaxel chemotherapy interposed with involved field radiation for advanced endometrial cancer.
Lupe K; D'Souza DP; Kwon JS; Radwan JS; Harle IA; Hammond JA; Carey MS
Gynecol Oncol; 2009 Jul; 114(1):94-8. PubMed ID: 19406459
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin and paclitaxel in advanced or metastatic endometrial cancer.
Pectasides D; Xiros N; Papaxoinis G; Pectasides E; Sykiotis C; Koumarianou A; Psyrri A; Gaglia A; Kassanos D; Gouveris P; Panayiotidis J; Fountzilas G; Economopoulos T
Gynecol Oncol; 2008 May; 109(2):250-4. PubMed ID: 18299146
[TBL] [Abstract][Full Text] [Related]
11. Predictive value of the combined serum CA 125 and TPS during chemotherapy and before second-look laparotomy in epithelial ovarian cancer.
Senapad S; Neungton S; Thirapakawong C; Suphanit I; Hangsubcharoen M; Thamintorn K
Anticancer Res; 2000; 20(2B):1297-300. PubMed ID: 10810438
[TBL] [Abstract][Full Text] [Related]
12. Carboplatin plus paclitaxel in the treatment of gynecologic malignancies: the Cleveland Clinic experience.
Markman M; Kennedy A; Webster K; Kulp B; Peterson G; Belinson J
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-26-S15-29. PubMed ID: 9346218
[TBL] [Abstract][Full Text] [Related]
13. Complete remission of uterine endometrial cancer with multiple lung metastases treated by paclitaxel and carboplatin.
Niwa K; Kometani K; Sekiya T; Nakazawa K; Kanakura Y
Int J Clin Oncol; 2002 Jun; 7(3):197-200. PubMed ID: 12109523
[TBL] [Abstract][Full Text] [Related]
14. Value of serum CA125 levels in patients with high-risk, early stage epithelial ovarian cancer.
Kang WD; Choi HS; Kim SM
Gynecol Oncol; 2010 Jan; 116(1):57-60. PubMed ID: 19818996
[TBL] [Abstract][Full Text] [Related]
15. [Successful treatment of endometrial carcinoma associated with lung metastasis by paclitaxel and carboplatin chemotherapy].
Tohya T; Onoda C; Yoshimura T; Kagami T
Gan To Kagaku Ryoho; 2004 Jun; 31(6):949-51. PubMed ID: 15222119
[TBL] [Abstract][Full Text] [Related]
16. Reuse of carboplatin and paclitaxel in patients with relapsed endometrial cancer--the British Columbia Cancer Agency experience.
Mazgani M; Le N; Hoskins PJ;
Gynecol Oncol; 2008 Dec; 111(3):474-7. PubMed ID: 18929402
[TBL] [Abstract][Full Text] [Related]
17. The relationship between histology and outcome in advanced and recurrent endometrial cancer patients participating in first-line chemotherapy trials: a Gynecologic Oncology Group study.
McMeekin DS; Filiaci VL; Thigpen JT; Gallion HH; Fleming GF; Rodgers WH;
Gynecol Oncol; 2007 Jul; 106(1):16-22. PubMed ID: 17574073
[TBL] [Abstract][Full Text] [Related]
18. Carboplatin and paclitaxel for the treatment of advanced or recurrent endometrial cancer.
Akram T; Maseelall P; Fanning J
Am J Obstet Gynecol; 2005 May; 192(5):1365-7. PubMed ID: 15902110
[TBL] [Abstract][Full Text] [Related]
19. The role of multi-modality adjuvant chemotherapy and radiation in women with advanced stage endometrial cancer.
Alvarez Secord A; Havrilesky LJ; Bae-Jump V; Chin J; Calingaert B; Bland A; Rutledge TL; Berchuck A; Clarke-Pearson DL; Gehrig PA
Gynecol Oncol; 2007 Nov; 107(2):285-91. PubMed ID: 17688923
[TBL] [Abstract][Full Text] [Related]
20. Paclitaxel/carboplatin versus cyclophosphamide/adriamycin/cisplatin as postoperative adjuvant chemotherapy for advanced endometrial adenocarcinoma.
Hidaka T; Nakamura T; Shima T; Yuki H; Saito S
J Obstet Gynaecol Res; 2006 Jun; 32(3):330-7. PubMed ID: 16764625
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
